Clinical Staging in Carcinoma of the Prostate: Current Aspects

Schmitz‐Dräger, Bernd J.; Ebert, Thomas; Ackermann, R.

doi:10.1007/978-3-642-84583-3_3

Cited by 1 publication

(3 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5). A false negative rate of 2% has been reported in prostate cancer [14]. The bone scan can identify incidental renal obstruction or large renal masses which may accompany prostate cancer.…”

Section: Staging With Imaging (Bone Metastases)mentioning

confidence: 98%

“…Clinical staging based on the DRE is inaccurate and understages the local extent of the tumor in 2 1 -5 2 % of patients [14,18]. This has prompted investigators to evaluate other techniques, specifically TRUS and MRI for local staging.…”

Section: Transrectal Ultrasoundmentioning

confidence: 99%

“…The sensitivity of CT for nodal involvement varies from 0% for small nodes with microscopic disease to 72% for more advanced disease [14,19]. False negatives result from microscopic nodal invasion within a node of normal size [17].…”

Section: Staging With Imaging (Nodal Metastases)mentioning

confidence: 99%

See 2 more Smart Citations

Imaging of prostate cancer

1995

Abdom Imaging

View full text Add to dashboard Cite

Prostate cancer diagnosis and treatment is fast emerging as a major health care issue in the United States. However, there are great uncertainties about the value of specific tests and therapies. Imaging modalities play a major role in the current management of patients with prostate cancer and this role is likely to expand in the future. Transrectal ultrasound is used to identify nonpalpable lesions, direct systematic biopsies, determine gland volume and stage prostate cancers. For staging skeletal metastases, the bone scan is acknowledged as the best method, however controversy surrounds its routine use in patients with low prostate specific antigen (PSA) values. Computed tomography (CT) and transrectal ultrasound have limited value in detecting extracapsular disease but CT can be used in conjunction with percutaneous biopsy to identify nodal metastases. The role of Endorectal coil MRI is currently evolving in the wake of a disappointing multi-institutional trial but MRI still holds the most promise for accurately detecting local extent of prostate cancer. New radiolabeled techniques with monoclonal antibodies and peptide imaging are also having early but promising results. The role of imaging in prostate cancer is continuing to evolve as technology and knowledge about prostate cancer biology improves and health care economics force a more judicious use of imaging resources.

show abstract

Section: Staging With Imaging (Bone Metastases)mentioning

confidence: 98%

Section: Transrectal Ultrasoundmentioning

confidence: 99%